CLIENT & SAMPLE INFORMATION

Client	TriVial BioWorks	**Certified Date**	10/24/2026
Lot / Batch	TS500-0930	**Product**	Tesofensine

This Certificate of Analysis reports the identity, chromatographic purity and active content per tablet of the product described above. The contents of each tablet tested were extracted and analyzed by reverse-phase HPLC with UV detection; purity is reported as area percent of the integrated chromatogram and content against a weighed reference standard. Identity is established by liquid chromatography-mass spectrometry against the compound's theoretical monoisotopic mass. The results relate only to the sample as received.

ANALYTICAL RESULTS


Test	Specification	Result	Status
Chromatographic Purity RP-HPLC | C18 | DAD @ 220 nm | area %	>= 98.0%	99.847%	PASS
Identity Confirmation LC-MS (ESI) | multiply-charged envelope vs. theoretical mass	Tesofensine	Tesofensine	PASS
Content per Tablet RP-HPLC against weighed reference standard	500 mcg	504.57 mcg	PASS


PHYSICOCHEMICAL PROPERTIES

Property	Specification	Result	Status
Appearance / Color	Conforms	Conforms	PASS
Physical Form	Tablet	Tablet	PASS
Tablet Integrity	Intact, no leakage	Conforms	PASS
Visible Foreign Matter	Essentially free	Conforms	PASS

CHROMATOGRAM

Method: RP-HPLC | Column: C18 | Detection: DAD @ 220 nm





Area percent of the principal peak against the total integrated area, excluding the solvent front and system peaks. Identity is not established by retention time alone -- see the mass spectrum above.